ARDS receives grant from the Bill & Melinda Gates Foundation

ARDS Aridis Pharmaceuticals received a grant award from the Bill & Melinda Gates Foundation to evaluate the application of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies (mAbs) against influenza and SARS-CoV2.

Aridis Pharmaceuticals is a stock with a mk cap of only 28.249Mil.

Before Aridis, Bill & Melinda Gates Foundation Covid-19 Response investments were in giant companies like: Abbott Laboratories, Gavi / Serum, Lilly mAb, SD Biosensor, UNICEF VII and World Health Organization.

AstraZeneca PLC ( AZN ) has a stake in Aridis Pharmaceuticals.
CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune.
Aridis Pharmaceuticals can be a potential buyout for AZN .

Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."

Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment!

Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."

ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.

It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.

With this investment, i think ARDS is at least an 100Mil mk cap stock.

So 4X from here.